Micell Technologies, Inc., is organized around advancing combination product therapies in the cardiovascular, orthopedic, and drug-delivery areas. The firm's Supercritical Fluid Technology consists of patented processes and methods for surface modifications of medical devices with specific focus on improvements to current polymer based drug-eluting technologies. Included in the firms technology platform are exclusively licensed patents from Pacific Northwest National Laboratory, a U.S. Department of Energy laboratory, managed by Battelle. For over a decade, Micell has teamed with renowned medical and scientific innovators to realize the singular vision: to lead in the development of advanced vascular medical devices with innovative drug delivery systems. The technology is being perfected to deliver a best-in-class coronary stent system, MiStent SES. the firm's patented drug application methodology is the major factor in the success of this system. Micell employs a supercritical fluid technology developed in conjunction with Pacific Northwest National Laboratory, a U.S. Department of Energy laboratory managed by Battelle Memorial Institute. This solvent-free technology, used in applying the polymer component to the stent platform, preserves the crystalline integrity of the drug during the coating process. Fusing the polymer, applied using supercritical fluid technology, and the dry crystalline form of the drug, creates a smooth, uniform, well-adhered coating on the stent.
